At TCR² Therapeutics, full engagement isn’t just the mantra of our scientific strategy — it’s our approach to life. We bring our whole selves and our passion to everything we do.
We’re proud to be pioneering the development of novel therapies that use the T-cell receptor (TCR) complex to fight both solid tumors and hematologic malignancies. Our unique TRuC-T cells harness signaling from the entire TCR complex, independent of HLA type, to specifically recognize and kill cancer cells, expanding the possibilities for patients.
- We Are…
- Our Leaders
- Our Board
- Our Service
“I am proud to lead this diverse team of exceptional people. Every day we have the chance to transform the field of cancer immunotherapy, save lives, and leave a meaningful legacy in the world.”
– Dr. Garry Menzel,
President and Chief Executive Officer
We Are…
Passion is in our DNA. We seek out teammates that beam with passion for life and immerse themselves with excitement in everything they do.
We pride ourselves on deep subject knowledge and good judgment – and we know how to apply and effectively communicate it to achieve our goals.
We don’t fear change. We embrace it and drive it. We take the initiative to solve problems, make good decisions, and inspire others to do likewise.
“Book smarts” aren’t enough here. We also look for emotional intelligence – the ability to read people, situations, and interpersonal dynamics; consider other viewpoints; and give and receive feedback with care and candor.
We are more than a company. We are a diverse and inclusive team. We work together across functions, levels, and locations, and we put the needs of the team above our own. We respect and trust each other. At TCR2, we provide a welcoming environment.
We are focused on getting results! We work hard, move quickly, rely on data, and focus on outcomes – and when priorities, scope or resources change, we pivot so we can do what needs to be done.
Executive Committee
Dr. Menzel joined TCR² in 2016 as a Director and Chief Executive Officer. He has over 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. His versatile career has included operational roles covering drug development, manufacturing, commercialization, financing, and M&A. Prior to TCR², he was the Chief Financial Officer at DaVita Healthcare (NYSE:DVA), a kidney dialysis and primary care physician company, and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS), a microRNA therapy company. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse where he advised on more than $100 billion in strategic transactions. In addition, he was a consultant with Bain & Company. Dr. Menzel was also a founding board member of Fierce 15 award winner Black Diamond Therapeutics (NASDAQ: BDTX), a clinical stage precision oncology company, and serves as chair of the audit committee. He also currently serves as a board member of Stoke Therapeutics (NASDAQ: STOK), a clinical stage biotechnology company using novel antisense oligonucleotide medicines to treat severe genetic diseases. He earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a M.B.A. from the Stanford Graduate School of Business.
Dr. Harrison joined TCR2 in 2022 as Chief Business and Strategy Officer. She brings nearly 20 years of global experience working on strategic planning, portfolio management and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics where she led its acquisition by Pfizer for $2.22 billion in November 2021. Before that, Dr. Harrison served in strategic and research roles within RA Capital Management and as Head of Rare Diseases at Imbria Pharmaceuticals. Earlier in her career, she was Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research as well as a consultant at Bain & Company where she advised on corporate strategic and operational programs. Dr. Harrison holds a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. from The University of Queensland.
Dr. Justice joined TCR² in 2019 as Chief People Officer. She brings nearly 20 years of experience in healthcare, medical affairs and human resources leadership. Prior to joining, she was Executive Vice President and Chief Human Resources Officer at Surgery Partners, playing a critical role in leading talent management strategy and launching a multi-year rewards strategy to incentivize organic growth. Before that, Dr. Justice worked at Biogen as the Chief Learning Officer where she assumed a variety of responsibilities including creating and leading a centralized learning organization supporting 14,000 people across all departments and geographies, spearheading the implementation of a learning technology system, and making learning a competitive force with measurable business impact. Earlier at Biogen, Angela served as Senior Director of Global Medical Affair and was an active member of the Human Resources Leadership Team. Previously, she held leadership roles at EMD Serono, the National MS Society and was a management consultant at McKinsey & Company. Dr. Justice received her Ph.D. in Biopsychology from the University of Chicago.
Mr. Olagunju is Chief Operating Officer and joined TCR² in 2021 as Chief Technical Officer. He brings over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining the Company, he was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, Mr. Olagunju was Vice President of Global Patient Operations at bluebird bio, Inc., where he held several roles of increasing responsibility and was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an M.B.A. from the University of Washington and a B.S. in Biology from the University of Illinois at Urbana-Champaign.
Dr. Quintás-Cardama joined TCR² in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás-Cardama was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás-Cardama earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.
Mr. Sullivan joined to TCR² in 2022 as Chief Financial Officer. He brings nearly two decades of finance and operations experience in the biotechnology industry working on financial management, strategic planning, and fundraising and capital market transactions across the public and private markets. Prior to joining the Company, he was President, Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics where he led finance, business development and corporate operations. Before that, Mr. Sullivan led finance as Senior Vice President at Gemini Therapeutics and Oncorus. Earlier in his career, he held senior financial management positions at bluebird bio and Merrimack Pharmaceuticals. Mr. Sullivan holds a B.S. in Accountancy from Bentley University and is a Certified Public Accountant (C.P.A.).
Operational Leaders
Dr. Gunn joined TCR² in 2022 as Vice President of Medical Affairs. Prior to joining the Company, she was a Managing Director of PharmStars, a pharma-focused accelerator for digital health startups. Before that, Laura served in various roles of increasing responsibility at Biogen, including Head of Scientific Partnerships and Chief Learning Officer. Earlier in her career, she served as Senior Medical Science Liaison at EMD Serono and Cancer Diagnostic Consultant at Quest Diagnostics. Dr. Gunn holds a Ph.D. and an M.S. Environmental Health Sciences, Toxicology and Molecular Epidemiology from the University of California, Berkeley and a B.S. in Biology and Philosophy from Simmons University.
Dr. Khatiwala is Vice President of Process and Analytical Development at TCR² after having joined in 2021. Prior to TCR², he was a Senior Director of Manufacturing Technical Services at Atara Biotherapeutics, where he oversaw tech transfer, MSAT, late-stage process development and process validation for the company’s lead allogenic T-cell asset. Before that, Dr. Khatiwala served in various roles of increasing responsibility at Organovo Holdings, where he focused on tissue production and process development, bioprocess technical operations and platform operations. Earlier in his career, he served in various research roles at University of California, Irvine. Dr. Khatiwala earned his Ph.D. in Biochemical Engineering and MS in Biochemical Engineering from University of California, Irvine and his B.E. in Chemical Engineering from University of Mumbai.
Ms. Muzithras joined TCR² in 2020 as Vice President of Regulatory Affairs. With over 25 years of global regulatory experience focusing on cell and gene therapy, oncology and vaccines, she most recently served as Executive Director of Global Regulatory Affairs at Bristol Myers Squibb (formerly Celgene Corporation), where she oversaw the development of novel cell and gene therapy products, biologicals such as T-cell engagers and antibody drug conjugates, and small molecules for hematologic diseases in multiple myeloma. Prior to Bristol Myers Squibb, Viera worked at Novartis Pharmaceuticals as Senior Director of Regulatory Affairs and Global Regulatory Director, where she was responsible for leading the global regulatory strategy and preparation and submission of the New Biologics License Application for Kymriah, a genetically modified autologous T cell immunotherapy targeting CD19. Earlier in her career, Viera served in various regulatory affairs roles at Bayer AG, Sanofi S.A., and Pfizer. Viera received a B.A. in Biochemistry from Rutgers, The State University of New Jersey.
Mr. Roomberg is Vice President, Corporate Controller at TCR² after having joined in 2019. Prior to TCR², he served in consulting roles for S.E.C registrants where he provided all aspects of financial operation guidance including preparation of public filing materials, M&A due diligence, integration and reporting, and implantation of new GAAP standards. Before that, Mr. Roomberg served as Controller for TerraForm Global, Inc, a world-wide renewable energy company, Director of SEC Reporting and Technical Accounting at Engility Holdings, Inc., a federal government services contractor, and Director of Financial Reporting, Tax and Accounting Policy at NCI, Inc. a federal government contractor. Earlier in his career, he served as an Adjunct Professor for Corporate Financial Reporting at George Mason University and as an Assistant Controller at BearingPoint, formerly KPMG Consulting. Mr. Roomberg is a C.P.A. and earned his B.Sc. in Accounting from Penn State University.
Ms. Siegel is Genersal Counsel and joined TCR² in 2018 as Head of Legal and Corporate Secretary. Prior to TCR², she was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle, from initial formation through venture financings, initial public offerings, follow-on offerings, strategic acquisitions and successful exit events. Ms. Siegel serves on the board of trustees of the Neighborhood House Charter School. She received her J.D. from Boston University School of Law and her B.S. in Anthropological Sciences and Philosophy from the Ohio State University.
Mr. Tighe joined TCR² in 2019 as Vice President of Translational Research. He brings over 25 years of experience in early clinical development and IND preparation while at large pharmaceuticals and biotechnology companies. Previously, he served as Vice President of Translational Immunology and Immunopharmacology at Compass Therapeutics, where he led the discovery and IND approval of CTX-471, a CD137 agonist antibody, and built the cellular immunology and autoimmunity research teams. Prior to Compass, he held several positions of increasing responsibility at EMD Serono, where he was a major contributor to the success of three INDs including the NHS-IL12 immunocytokine, the now approved anti-PD-L1 antibody avelumab (Bavencio™) and M7824, an anti-PD-L1/TGFβ-trap molecule. Earlier in his career, Robert served in various research roles at EMD Lexigen Research Center, ArQule, The Jackson Laboratory, Massachusetts Institute of Technology, Genetix Pharmaceuticals (now bluebird bio) and the Whitehead Institute for Biomedical Research. Robert focused on Biology and Chemistry at Salem State College.
Mr. Zikaras is Vice President of Development Operations at TCR² having joined in June of 2018. Prior to TCR², he was a Director of Clinical Development at Actinium Pharmaceuticals, where he was the program lead for Iomab-B, an Iodine-131 anti-CD45 antibody. Before that, Kevin served as Clinical Protocol Manager at Bristol Myers Squibb where he led global development immuno-oncology clinical trials, including the first study ever approved in the United States with a checkpoint inhibitor. Earlier in his career, he held several clinical roles with increasing responsibility at Columbia University Medical Center – Herbert Irving Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center. Kevin earned his BA in Biology from Bowdoin College, his MS in Strategic Regulatory Affairs from Northeastern University, his MS in Healthcare Leadership from Weill Cornell Medical College, and his MBA from Cornell Johnson Graduate School of Management.
Board of Directors
Dr. Allen is a co-founder of Gritstone Oncology, Inc. (NASDAQ:GRTS), and has served as its President, Chief Executive Officer, and board member since its inception in August 2015. Prior to Gritstone, in April 2009, Dr. Allen co-founded Clovis Oncology, Inc., or Clovis, a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was Chief Medical Officer at Pharmion Corporation from 2006 to 2008 (acquired by Celgene for $2.9B). Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme, Inc., and Sierra Oncology, Inc., both public biopharmaceutical companies, and Revitope Oncology, Inc, a private biotechnology company. Dr. Allen previously served on the board of directors of Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology, and Medicine in London.
Dr. Gadicke is co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities). Dr. Gadicke led the company-building efforts of several of MPM’s most successful investments including BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), Pharmasset (acquired by Gilead Sciences), and Radius Health – companies that are helping thousands of patients live longer and vastly improved lives. Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to founding MPM, Dr. Gadicke was at The Boston Consulting Group. Dr. Gadicke, active in guiding MPM portfolio companies, also serves as Chairman of the Board at Cullinan Oncology and is a member of the Board of ElevateBio and iTeos Therapeutics. He is also a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of the Massachusetts General Hospital. He received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.
Dr. Axel Hoos is Chief Executive Officer of Scorpion Therapeutics. Previously, he was Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). As R&D Governance Chair he oversees technical and funding review committees. As Therapeutic Area Head he is responsible for the Oncology business including discovery and development with the four focus areas of immuno-oncology, epigenetics, cell & gene therapy and synthetic lethality. He has also been responsible for leading business development portfolio expansions including the acquisition of Tesaro and the cell & gene therapy licensing agreements with Adaptimmune, Lyell and Immatics. Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute, is Co-founder and Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium and Scientific Advisory Board Member of the Cancer Research Institute. Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb where he developed Yervoy (Ipilimumab) which was the first checkpoint inhibitor drug in immuno-oncology. The discovery of ipilimumab’s scientific mechanism was honored with the Nobel Prize for Physiology or Medicine to Dr. James Allison in 2018. Dr. Hoos was also Senior Director of Clinical Development at Agenus Bio. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ). He trained in surgery at the Technical University in Munich and at Memorial Sloan-Kettering Cancer Center in New York City (where he also studied molecular pathology and tumor immunology). He is an alumnus of the Program for Leadership Development at Harvard Business School.
Dr. Menzel joined TCR² in 2016 as a Director and Chief Executive Officer. He has over 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. His versatile career has included operational roles covering drug development, manufacturing, commercialization, financing, and M&A. Prior to TCR², he was the Chief Financial Officer at DaVita Healthcare (NYSE:DVA), a kidney dialysis and primary care physician company, and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS), a microRNA therapy company. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse where he advised on more than $100 billion in strategic transactions. In addition, he was a consultant with Bain & Company. Dr. Menzel was also a founding board member of Fierce 15 award winner Black Diamond Therapeutics (NASDAQ: BDTX), a clinical stage precision oncology company, and serves as chair of the audit committee. He also currently serves as a board member of Stoke Therapeutics (NASDAQ: STOK), a clinical stage biotechnology company using novel antisense oligonucleotide medicines to treat severe genetic diseases. He earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a M.B.A. from the Stanford Graduate School of Business.
Dr. Gibson is Chief Executive Officer of Adanate. Prior to Adanate, in October 2016, Dr. Gibson served as Chief Scientific Officer of COI Pharmaceuticals. In this role, he is responsible for the creation of new biotechnology companies that advance innovative therapeutics into areas of high unmet medical need. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (temozolomide, sorafenib, erlotnib, and crizotinib). Dr. Gibson has held numerous senior positions within the biotechnology and pharmaceutical industry, including Chief Scientific Officer of Regulus Therapeutics, Chief Scientific Officer and Oncology Therapeutic Area Head at Pfizer Oncology, and Chief Scientific Officer at OSI Pharmaceuticals. Dr. Gibson has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston.
Dr. Hegde is Chief Scientific Officer of Foundation Medicine Inc., where she oversees clinical product development, cancer genomics, regulatory and early stage research to advance their leading comprehensive genomic profiling portfolio. Previously, Dr. Hegde held roles of increasing responsibility at Genentech for 12 years, where she served as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy and was responsible for clinical translation strategies for more than 18 therapeutic programs in over 100 Phase I-III global clinical trials. Dr. Hegde was also instrumental in the approvals for Tecentriq® (atezolizumab), a PD-L1 immunotherapy, in both the United States and European Union, as well as its forthcoming diagnostic filings. Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. She completed her post-doctoral fellowship at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy degree from Mumbai University, India.
Ms. Tomasello served as the Chief Commercial Officer of Kite Pharma, where she oversaw the global commercialization of Yescarta, from 2015 to 2018 including through its acquisition by Gilead for $11.9 billion in October 2017. She was previously Chief Commercial Officer at Pharmacyclics, where she led commercial and medical affairs activities for Imbruvica®, a first-in-class treatment for hematologic malignancies, from August 2014 until its acquisition by AbbVie for $21.0 billion in August 2015. Prior to Pharmacyclics, Ms. Tomasello served in leading commercial roles with multiple major pharmaceutical companies, including Celgene as President of the Americas Hematology and Oncology, where she led the company through five successful product launches encompassing 11 indications and played a critical role in acquisitions. Ms. Tomasello received her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University in Kentucky.
Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as Senior Vice President and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure, a publicly traded biopharmaceutical company, since April 2019, Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company, since August 2016 and Viking Therapeutics, a publicly traded biopharmaceutical company, since May 2014. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
Advisors
Managing Director, MPM Capital, Cambridge, MA
BiTE technology pioneer and T cell biologist: developed the worlds first bispecific antibody, Blincyto
Member of TCR² Board of Directors
Managing Director, MPM Capital, Cambridge, MA
Board of Directors Member – Adverum Biotechnologies, Semma Therapeutics, Oncorus, and CODA Biotherapeutics
Cell therapy manufacturing expert: Developed bluebird bio’s strategy as CSO from 2010-2015
Yetta Deitch Novotny Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
Chief of the Section of Cellular Therapy and Transplant, Children’s Hospital of Philadelphia, PA
CAR-T development pioneer: Treated Emily Whitehead, the first pediatric patient to receive CAR-T therapy
Professor and Chairman, Institute of Biology III (Molecular Immunology) and Centre for Biological Signaling Studies (BIOSS), University of Freiburg, Germany
Leading researcher on T-cell receptor signaling: Studies TCR structure, subunit function, and downstream signaling
Professor and Chairman, Department of Cancer Immunology and
Virology Director of Center for Cancer Immunotherapy Research, Boston, MA
Prominent T-cell biologist and cancer immunologist: Researches T-cell regulation and the tumor microenvironment’s effect on T cells
Our Service
At TCR², we are very active in giving back to our local and patient communities. TCR² Cares is an employee-initiated program established in 2017 that focuses on giving back to our community in ways that connect to our corporate goal of curing cancer. As a result, we tend to support cancer-related charities and those involved in educating children about science, especially those from underserved communities. Check out some of our recent projects:
TCR² served up breakfast and packed lunches for guests of The Pine Street Inn.
The Pine Street Inn is a Boston based network of shelters that has been helping homeless individuals move from the streets, to shelter, to a home since 1969. They provide street outreach, emergency services, supportive housing, job training and connections to employment through their program.
Inspired by CEO Garry Menzel’s running of the 2019 Boston Marathon, a group of 10 TRuCers has joined the Dana-Farber Marathon Challenge Team, with a goal of raising over $100,000 for Dana-Farber cancer research and completing the 2020 Boston Marathon.
The Dana-Farber Cancer Insitute is a comprehensive cancer research and treatment center in Boston, MA. All funds raised by the Dana-Farber Marathon Challenge go toward The Claudia Adams Barr Program in Innovative Basic Cancer Research. The Barr Program supports early-career scientists across a range of cancer research disciplines. Based on a highly selective process, the Barr Program chooses the brightest scientists and funds their most innovative ideas to propel basic research discoveries that transform cancer treatment.
Every month, TCR² chefs volunteer to cook dinner for cancer patients and their families who are guests of The Boston House.
The Boston House is a home-away-from-home for families who come to Boston seeking treatment for childhood cancers and other life-threatening hematological illnesses at Dana-Farber Boston Children’s Cancer and Blood Disorders Center. Since 1979, guests of The Boston House have been provided a low-cost housing alternative, a respite from hospital life, and a place where families can be together, share stories with other families in a similar situation, and lean on one another for support.
For the second consecutive year, TCR² raised over $12,000 and joined more than 8,200 walkers in September 2019 to support cancer patients and research for cancer cures at the Boston Marathon® Jimmy Fund Walk for Dana-Farber Cancer Institute. Members of the TCR² team walked together along the 5K, 10K and half marathon courses to show our strength in numbers and join the broader community raising money for cancer patients and cancer research.
The Jimmy Fund, founded in 1948, solely supports Boston’s Dana-Faber Cancer Institute, raising resources and awareness for adult and pediatric cancer care and research to improve the chances of survival for cancer patients around the world. Since its inception, the Jimmy Fund has raised millions of dollars for its cause, through thousands of community fundraising events like the Jimmy Fund Walk.
TCR² TRuCers (self proclaimed name of TCR² team members pronounced trucker) were inspired at their Science Offsite Meeting in November, 2018 by special guest speakers Diane and Bob Riche of Ovarian Cancer 101 and Andy Richards of The Boston House to keep working towards the common goal of curing cancer. The team bonded as they constructed care packages containing activities, soothing aids and motivational messages for young cancer patients staying at The Boston House.